Clinical Trial Update: Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the analgesic efficacy and safety of ADL5859 in subjects with acute dental pain after third molar extraction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pain

Drugs mentioned

• ADL5859

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Acute Pain | Phase 2 | Status: COMPLETED